There was no evidence that the association between PDE5 inhibitor use and melanoma risk differed by specific PDE5 inhibitor drug (p = 0.42), but the number of melanoma outcomes among men on drugs other than sildenafil was small (n = 50 and n = 12 events for tadalafil and vardenafil, respectively), leading to limited power. Here, PDE5A is linked to melanoma.